Canada Life’s Arcutis Biotherapeutics ARQT Stock Holding History

Canada Life’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$335K	Hold	12,816	–	–	﹤0.01%	1539
2026 Q1	$303K	Hold	12,816	–	–	﹤0.01%	1554
2025 Q4	$372K	Sell	12,816 -13,013	-50%	-$333K	﹤0.01%	1557
2025 Q3	$481K	Hold	25,829	–	–	﹤0.01%	1608
2025 Q2	$363K	Buy	25,829 +13,013	+102%	+$182K	﹤0.01%	1655
2025 Q1	$201K	Buy	+12,816	New	+$181K	﹤0.01%	1720
2024 Q4	–	Sell	-8,233	Closed	-$77K	–	2027
2024 Q3	$77K	Hold	8,233	–	–	﹤0.01%	1898
2024 Q2	$76K	Buy	+8,233	New	+$74.5K	﹤0.01%	1919
2023 Q4	–	Sell	-2,159	Closed	-$11K	–	2166
2023 Q3	$11K	Hold	2,159	–	–	﹤0.01%	2202
2023 Q2	$21K	Hold	2,159	–	–	﹤0.01%	2131
2023 Q1	$24K	Hold	2,159	–	–	﹤0.01%	2176
2022 Q4	$32K	Buy	2,159 +941	+77%	+$16.4K	﹤0.01%	2166
2022 Q3	$23K	Hold	1,218	–	–	﹤0.01%	2240
2022 Q2	$26K	Hold	1,218	–	–	﹤0.01%	2209
2022 Q1	$25K	Hold	1,218	–	–	﹤0.01%	2314
2021 Q4	$25K	Hold	1,218	–	–	﹤0.01%	2330
2021 Q3	$29K	Hold	1,218	–	–	﹤0.01%	2362
2021 Q2	$33K	Hold	1,218	–	–	﹤0.01%	2377
2021 Q1	$35K	Hold	1,218	–	–	﹤0.01%	2401
2020 Q4	$34K	Hold	1,218	–	–	﹤0.01%	2405
2020 Q3	$36K	Hold	1,218	–	–	﹤0.01%	2259
2020 Q2	$37K	Buy	+1,218	New	+$35.2K	﹤0.01%	2322

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Canada Life's ARQT Position: Q2 2026 in Review

Canada Life held its Arcutis Biotherapeutics (ARQT) position steady in Q2 2026 at 12,816 shares worth $335K. The position accounts for ﹤0.01% of the portfolio, ranked #1539.

Canada Life first reported a position in ARQT in Q2 2020 and has held it in 22 quarters since. The position peaked at $481K in Q3 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Canada Life held 12,816 shares of Arcutis Biotherapeutics worth $335K as of Q2 2026.
Canada Life left its Arcutis Biotherapeutics share count unchanged in Q2 2026.
Arcutis Biotherapeutics made up ﹤0.01% of Canada Life's portfolio in Q2 2026, its #1539 holding.
Canada Life first reported a position in Arcutis Biotherapeutics in Q2 2020 and has held it in 22 quarters since.
Canada Life's Arcutis Biotherapeutics position peaked at $481K in Q3 2025.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Canada Life's 13F filing for Q2 2026, filed 13 Aug 2026.